Tonghua Dongbao Pharmaceutical Co Ltd (600867) - Total Liabilities
Based on the latest financial reports, Tonghua Dongbao Pharmaceutical Co Ltd (600867) has total liabilities worth CN¥1.01 Billion CNY (≈ $148.11 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Tonghua Dongbao Pharmaceutical Co Ltd - Total Liabilities Trend (1994–2025)
This chart illustrates how Tonghua Dongbao Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See Tonghua Dongbao Pharmaceutical Co Ltd (600867) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Tonghua Dongbao Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Tonghua Dongbao Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
BaoJi Titanium Industry Co Ltd
SHG:600456
|
China | CN¥7.45 Billion |
|
Payoneer Global Inc
NASDAQ:PAYO
|
USA | $7.94 Billion |
|
Hyosung Corp
KO:004800
|
Korea | ₩2.53 Trillion |
|
Elkem ASA
OL:ELK
|
Norway | Nkr23.46 Billion |
|
Maxvision Technology Corp
SHE:002990
|
China | CN¥1.10 Billion |
|
GavYam Lands Corp Ltd
TA:GVYM
|
Israel | ILA12.32 Billion |
|
Shenzhen Mason Technologies Co Ltd
SHE:002654
|
China | CN¥3.03 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $107.77 Million |
Liability Composition Analysis (1994–2025)
This chart breaks down Tonghua Dongbao Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Tonghua Dongbao Pharmaceutical Co Ltd.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.84 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Tonghua Dongbao Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Tonghua Dongbao Pharmaceutical Co Ltd (1994–2025)
The table below shows the annual total liabilities of Tonghua Dongbao Pharmaceutical Co Ltd from 1994 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥798.84 Million ≈ $116.90 Million |
-18.33% |
| 2024-12-31 | CN¥978.08 Million ≈ $143.12 Million |
+76.21% |
| 2023-12-31 | CN¥555.08 Million ≈ $81.23 Million |
+176.52% |
| 2022-12-31 | CN¥200.74 Million ≈ $29.37 Million |
-33.06% |
| 2021-12-31 | CN¥299.87 Million ≈ $43.88 Million |
+23.00% |
| 2020-12-31 | CN¥243.80 Million ≈ $35.68 Million |
-28.52% |
| 2019-12-31 | CN¥341.10 Million ≈ $49.91 Million |
-53.21% |
| 2018-12-31 | CN¥729.06 Million ≈ $106.68 Million |
+238.63% |
| 2017-12-31 | CN¥215.30 Million ≈ $31.50 Million |
-70.50% |
| 2016-12-31 | CN¥729.76 Million ≈ $106.79 Million |
-44.26% |
| 2015-12-31 | CN¥1.31 Billion ≈ $191.56 Million |
+64.52% |
| 2014-12-31 | CN¥795.72 Million ≈ $116.44 Million |
+17.32% |
| 2013-12-31 | CN¥678.23 Million ≈ $99.25 Million |
+74.39% |
| 2012-12-31 | CN¥388.92 Million ≈ $56.91 Million |
+29.91% |
| 2011-12-31 | CN¥299.37 Million ≈ $43.81 Million |
-34.02% |
| 2010-12-31 | CN¥453.75 Million ≈ $66.40 Million |
-27.37% |
| 2009-12-31 | CN¥624.75 Million ≈ $91.42 Million |
-15.31% |
| 2008-12-31 | CN¥737.66 Million ≈ $107.94 Million |
+0.37% |
| 2007-12-31 | CN¥734.97 Million ≈ $107.55 Million |
+6.34% |
| 2006-12-31 | CN¥691.13 Million ≈ $101.13 Million |
+26.99% |
| 2005-12-31 | CN¥544.23 Million ≈ $79.64 Million |
+13.35% |
| 2004-12-31 | CN¥480.12 Million ≈ $70.26 Million |
+21.87% |
| 2003-12-31 | CN¥393.95 Million ≈ $57.65 Million |
+91.68% |
| 2002-12-31 | CN¥205.52 Million ≈ $30.07 Million |
+163.62% |
| 2001-12-31 | CN¥77.96 Million ≈ $11.41 Million |
+76.76% |
| 2000-12-31 | CN¥44.10 Million ≈ $6.45 Million |
-52.47% |
| 1999-12-31 | CN¥92.79 Million ≈ $13.58 Million |
-62.86% |
| 1998-12-31 | CN¥249.82 Million ≈ $36.56 Million |
+286.09% |
| 1997-12-31 | CN¥64.70 Million ≈ $9.47 Million |
+25.51% |
| 1996-12-31 | CN¥51.55 Million ≈ $7.54 Million |
-30.22% |
| 1995-12-31 | CN¥73.88 Million ≈ $10.81 Million |
+213.84% |
| 1994-12-31 | CN¥23.54 Million ≈ $3.44 Million |
-- |
About Tonghua Dongbao Pharmaceutical Co Ltd
Tonghua Dongbao Pharmaceutical Co., Ltd. researches, develops, produces, and markets pharmaceuticals in China. It offers human insulin injections; insulin glargine injections; insulin aspart injections; liraglutide injections; and proprietary Chinese medicine. The company also provides insulin pen and pen needles; and chronic disease management platform, a diabetes management platform for drug tr… Read more